CME Activities
- Frequently Asked Questions in Ovarian Cancer: How Does Emerging Evidence Impact the Answers?
- Improving Outcomes in Recurrent Ovarian Cancer: Emerging Treatments and Clinical Cases
- Ovarian Cancer Findings Support Antitumor Effects of Oral Antidiabetic
- BRCA1 and BRCA2 May Require Different Ovarian Cancer Treatments
- Targeted Therapies for Ovarian Cancer--The State of the Evidence
Latest Clinical Briefs in Ovarian Cancer
- Ovarian Cancer Findings Support Antitumor Effects of Oral Antidiabetic
- BRCA1 and BRCA2 May Require Different Ovarian Cancer Treatments
- New Gynecologic Cancer Surveillance Guidelines Issued
- Updated Ovarian Cancer Guidelines Offer a New Treatment Choice
- Growth Factor Neutralizing Agent Improves PFS in Ovarian Cancer
About Ovarian Cancer
-
Ovarian cancer is the second most common cancer of the female reproductive system in the United States and is the leading cause of death from a gynecologic cancer. Diagnosing ovarian cancer is difficult; currently available screening tests offer limited accuracy, challenging researchers to identify and develop more sensitive screening methods. The poor prognosis of ovarian cancer also challenges clinicians to stay on top of new data and other advances in the field to improve patient care and disease management.